Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Bacteria and Cancer
share announcement

Advances in Bacteria and Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 15 July 2025 | Viewed by 7438

Special Issue Editor

Dr. Alain P. Gobert

E-Mail Website
Guest Editor
Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN 37232-0252, USA
Interests: gastrointestinal inflammation; gastric cancer; colitis-associated carcinogenesis; colorectal cancer; polyamines; reactive aldehydes

Special Issue Information

Dear Colleagues,

Emerging evidence has pointed towards the extensive involvement of bacteria in cancer biology. They may regulate carcinogenesis, cancer progression, and metastasis, as well as response to treatments. This occurs through a direct effect on oncogenic signaling, or indirectly by modulating host immunes and/or metabolic responses. This Special Issue, “Advances in Bacteria and Cancer”, focuses on the identification and implication of different bacterial communities, including, but not limited to, pathogens, resident microbiota, tumor-associated bacteria, or probiotics in cancer. We will publish original articles and reviews on all types of cancer. Multi-omics, mechanistic, pre-clinical, and clinical investigations are welcome in this Special Issue.

Dr. Alain P. Gobert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pathogenic bacteria
  • microbiota
  • tumor-associated bacteria
  • probiotics
  • oncogenesis
  • metastasis
  • chemotherapy
  • cancerous cells
  • tumor microenvironment
  • cell signaling

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 6161 KiB  
Review
Towards Understanding Tumour Colonisation by Probiotic Bacterium E. coli Nissle 1917
by Georgette A. Radford, Laura Vrbanac, Rebekah T. de Nys, Daniel L. Worthley, Josephine A. Wright, Jeff Hasty and Susan L. Woods
Cancers 2024, 16(17), 2971; https://doi.org/10.3390/cancers16172971 - 26 Aug 2024
Viewed by 1354
Abstract
The last decade has seen a rapid increase in studies utilising a genetically modified probiotic, Escherichia coli Nissle 1917 (EcN), as a chassis for cancer treatment and detection. This approach relies on the ability of EcN to home to and selectively colonise tumours [...] Read more.
The last decade has seen a rapid increase in studies utilising a genetically modified probiotic, Escherichia coli Nissle 1917 (EcN), as a chassis for cancer treatment and detection. This approach relies on the ability of EcN to home to and selectively colonise tumours over normal tissue, a characteristic common to some bacteria that is thought to result from the low-oxygen, nutrient-rich and immune-privileged niche the tumour provides. Pre-clinical studies have used genetically modified EcN to deliver therapeutic payloads that show efficacy in reducing tumour burden as a result of high-tumour and low off-target colonisation. Most recently, the EcN chassis has been expanded into an effective tumour-detection tool. These advances provide strong justification for the movement of genetically modified EcN into clinical oncology trials. What is currently unknown in the field is a deep mechanistic understanding of how EcN distributes to and localises within tumours. This review summarises the existing EcN literature, with the inclusion of research undertaken with other tumour-homing and pathogenic bacteria, to provide insights into possible mechanisms of EcN tumour homing for future validation. Understanding exactly how and why EcN colonises neoplastic tissue will inform the design and testing of the next generation of EcN chassis strains to address biosafety and containment concerns and optimise the detection and treatment of cancer. Full article
(This article belongs to the Special Issue Advances in Bacteria and Cancer)
►▼ Show Figures

Figure 1

11 pages, 279 KiB  
Review
Helicobacter pylori Infection in Patients with Gastric Cancer: A 2024 Update
by Claudia Burz, Vlad Pop, Ciprian Silaghi, Iulia Lupan and Gabriel Samasca
Cancers 2024, 16(11), 1958; https://doi.org/10.3390/cancers16111958 - 22 May 2024
Viewed by 3473
Abstract
Numerous studies have been performed on Helicobacter pylori infection because of the high death rate linked to this illness and gastric cancer. An update on the key developments in recent years in the investigation of Helicobacter pylori and gastric cancer is the goal [...] Read more.
Numerous studies have been performed on Helicobacter pylori infection because of the high death rate linked to this illness and gastric cancer. An update on the key developments in recent years in the investigation of Helicobacter pylori and gastric cancer is the goal of this review. Using the search term “Helicobacter pylori, gastric cancer”, the PubMed database was searched. Only papers published in 2024 fulfilled the inclusion criteria. Because case report papers were not part of our investigation, they satisfied the exclusion criteria. Most of the research on the variable genes of Helicobacter pylori is guided by genetics to determine potential treatments. Studies on clinical treatments for the eradication of H. pylori with promising therapeutic options are needed. We found the fewest studies related to the immunopathology of H. pylori infection, which is still unknown. In conclusion, priority should be given to this kind of research. Full article
(This article belongs to the Special Issue Advances in Bacteria and Cancer)
14 pages, 1234 KiB  
Review
Bladder Cancer and Probiotics: What Do We Know So Far?
by Pedro Sánchez-Pellicer, Claudia Boix-Rodríguez, Adriana Hernández-Belmonte, Cristina de la Encarnación-Castellano, Alberto Mendiola-López, Eva Núñez-Delegido, Laura Navarro-Moratalla, Juan Agüera-Santos, Vicente Navarro-López and Juan Antonio Galán-Llopis
Cancers 2023, 15(23), 5551; https://doi.org/10.3390/cancers15235551 - 23 Nov 2023
Cited by 1 | Viewed by 2157
Abstract
Bladder cancer is around the 10th most diagnosed cancer, although has a considerable mortality. Recent research and new methodologies have discarded the historical dogma that the bladder (and urine) was sterile under normal conditions. Specifically, only a few studies have reported a detailed [...] Read more.
Bladder cancer is around the 10th most diagnosed cancer, although has a considerable mortality. Recent research and new methodologies have discarded the historical dogma that the bladder (and urine) was sterile under normal conditions. Specifically, only a few studies have reported a detailed analysis of the urinary microbiota in patients with bladder cancer, thus exhibiting a remarkable variability due to the low biomass of the urinary microbiota and the influence of many factors. Nevertheless, this research shows us signals that urinary microbiota is a factor to be considered in the pathophysiology of bladder cancer. More importantly, probiotics could be useful as an adjuvant therapy to reduce the recurrence rate or increase the disease-free period after surgery. In vitro studies and animal assays have shown promising results, but the research in this context has also been scarce, and only a few studies have been conducted in humans. In summary, there is little evidence of the possible beneficial effect of probiotics in controlling the overgrowth of genera that could be involved in the carcinogenesis of bladder cancer. This narrative review aims to compile all the evidence to date on the therapeutic potential of probiotics injected directly into the bladder or orally administered. Full article
(This article belongs to the Special Issue Advances in Bacteria and Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop